Clinical Trial Search

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 8 Participants

Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…

Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Cardiac Ejection Fraction as Measured by Echocardiogram — 54.6; 55.2 percentage of blood leaving the heart

Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44

Primary: Heart Failure Mortality — 8; 19 participants — p=0.01

Primary: Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs) — 1; 0; 0; 1 Participants

Primary: Number of Participants With Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs. — 1 Participants

Primary: Rate of Cardiac Amyloidosis Diagnosis — 24 Participants

Primary: Change in Diastolic Blood Pressure — -3.1; -3.3; -4.3; -2.6 mm Hg

Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…

Primary: Phase 2: Incidence of Treatment-emergent Adverse Events (TEAE) at 12 Months — 100; 100; 88.9; 92.9 percentage of participants

Primary: Number of Participants Experiencing Any of the Adjudicated Events — 0; 0; 0; 0 Participants

Primary: Number of Participants With Adverse Events (AEs). — 1; 3; 2; 0 Participants

Primary: Improvement in Left Ventricular Ejection Fraction — 42.1; 37.6 Percentage — p=0.267

Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…

Primary: A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT…

Primary: Prevalence of Transthyretin Cardiac Amyloidosis (ATTR-CA) in Cohort of Caribbean Hispanics and Blacks With Heart Failure (HF) — 7.8; 0 percentage of participants

Primary: Left Ventricular Strain — 0.2; 0.4 Percent change in circumference — p=0.5867

Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685

Primary: Change in Cardiac Diastolic Function as Measured by E' (cm/s) — -0.02; 0.55 cm/s — p=0.07

Primary: Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations — 8595; 5071 wins — p=0.0006

Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants

Primary: Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) — -3.86 meters

Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units

Primary: Changes in Strain Echocardiography — 9.1 percent LV shortening

Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants

Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506

Primary: Incidence of Dose Limiting or Intolerability Treatment Related Adverse Events — 45; 21; 40; 0 events